Transcriptome-based identification of tumor-reactive and bystander CD8


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
15 Nov 2023
Historique:
medline: 17 11 2023
pubmed: 15 11 2023
entrez: 15 11 2023
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is generally refractory to immune checkpoint blockade, although patients with genetically unstable tumors can show modest therapeutic benefit. We previously demonstrated the presence of tumor-reactive CD8

Identifiants

pubmed: 37967201
doi: 10.1126/scitranslmed.adh9562
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadh9562

Auteurs

Zibo Meng (Z)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China.

Aaron Rodriguez Ehrenfried (A)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Helmholtz-Institute for Translational Oncology by DKFZ (HI-TRON), 55131 Mainz, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Chin Leng Tan (CL)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.
Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, 69120 Heidelberg, Germany.

Laura K Steffens (LK)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Hannes Kehm (H)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Stefan Zens (S)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Claudia Lauenstein (C)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.

Alina Paul (A)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Marius Schwab (M)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.

Jonas D Förster (JD)

Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.
Division of Immunotherapy & Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Molecular Vaccine Design, German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany.

Mogjiborahman Salek (M)

Division of Immunotherapy & Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Molecular Vaccine Design, German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany.

Angelika B Riemer (AB)

Division of Immunotherapy & Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Molecular Vaccine Design, German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany.

Heshui Wu (H)

Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China.
Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China.

Christoph Eckert (C)

Pathology Institute, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Carl-Stephan Leonhardt (CS)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Oliver Strobel (O)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Michael Volkmar (M)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Helmholtz-Institute for Translational Oncology by DKFZ (HI-TRON), 55131 Mainz, Germany.

Isabel Poschke (I)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, 69120 Heidelberg, Germany.
Immune Monitoring Unit, National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.

Rienk Offringa (R)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, 69120 Heidelberg, Germany.
Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH